Centessa Pharmaceuticals (CNTA) Other Non-Current Liabilities (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Other Non-Current Liabilities of $29000.0 for Q1 2026, little changed year-over-year from $29000.0 in Q1 2025, and little changed on a QoQ basis from $29000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Other Non-Current Liabilities data on file, last reported at $29000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $29000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $29000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $29000.0 in Q1 2026 per CNTA's latest filing, from $29000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $43000.0 in Q1 2022 and bottomed at $29000.0 in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $29000.0 (2023), against an average of $31333.3.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities slumped 99.87%; it then changed 0.0% in 2024.
- Tracing CNTA's Other Non-Current Liabilities over 5 years: stood at $43000.0 in 2022, then plunged by 32.56% to $29000.0 in 2023, then changed by 0.0% to $29000.0 in 2024, then changed by 0.0% to $29000.0 in 2025, then changed by 0.0% to $29000.0 in 2026.
- Per Business Quant, the three latest CNTA Other Non-Current Liabilities figures stand at $29000.0 (Q1 2026), $29000.0 (Q4 2025), and $29000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 29,000.00 |
| Jun 30, 2022 | 43,000.00 |
| Mar 31, 2022 | 43,000.00 |
| Dec 31, 2021 | 37.70 Mn |
| Sep 30, 2021 | 33.93 Mn |
| Jun 30, 2021 | 33.93 Mn |